Kerry Stokes’ Media Executives Take Interest in Orthocell
What could justify Seven West Media’s striking attention toward the ASX-listed medtech firm Orthocell? The curiosity seems unusual given the company’s relatively small profile in the market.
Orthocell, based in Perth, develops advanced cell regeneration therapies aimed at repairing damaged tissues. The firm originated from the University of Western Australia in 2007 and currently holds a market capitalization fluctuating around $300 million.
Over the past year, Orthocell’s shares have climbed roughly 80 percent, signaling a strong upward trend for a company of its size. Despite this surge, Orthocell remains one of several small but promising medtech players on the Australian Securities Exchange.
“Most people wouldn’t have heard of Orthocell. It’s a Perth-based, ASX-listed medtech that makes cell regeneration therapies.”
Seven West Media’s keen focus on the company has raised eyebrows, hinting at potential underlying interests or strategic motives within the network’s investment sphere.
Author’s Summary
Seven West Media’s growing fascination with Orthocell highlights the rising profile of a small but fast-developing Australian medtech innovator.